Causes and Consequences of Primary Ovarian Insufficiency (Clinical POI)
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Eystein Husebye, prof
- Phone Number: +4755975000
- Email: eyhu@helse-bergen.no
Study Locations
-
-
-
Bergen, Norway
- Recruiting
- haukelandUH
-
Contact:
- Elinor Vogt, MD
- Phone Number: +4793899380
- Email: elinor.vogt@uib.no
-
Sub-Investigator:
- Marianne Oksnes, PHD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:Women 40 years or younger, more than 4 months amenorrhea, more than 2 FSH measurements in menopausal range (drawn at least 2 months apart), ability to provide informed concent -
Exclusion Criteria:History of oophorectomy, chemotherapy or radiation
-
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Autoimmune
Time Frame: one day
|
Prevalence of primary ovarian insufficiency (POI) with autoimmune etiology based on positive autoantibodies toward steroidogenic cells
|
one day
|
|
Genetic
Time Frame: one day
|
Prevalence of POI with genetic etiology defined by detection of genetic defects in a NGS panel
|
one day
|
|
Endocrine disrupting chemicals
Time Frame: one day
|
Characterize the cohort of women with POI, including testing for environmental factors
|
one day
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Phenotype description
Time Frame: one day
|
Describe phenotypical characteristics including menstrual characteristics, hormone profile, BMD
|
one day
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Kahtan Al-Azawy, MD, Haukeland University Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2018/1206
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.